Literature DB >> 20164467

Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.

Simon T Abrams1, Benjamin R B Brown, Mirko Zuzel, Joseph R Slupsky.   

Abstract

Chronic lymphocytic leukemia (CLL) is a malignant disease of mature B lymphocytes. We have previously shown that a characteristic feature of CLL cells are high levels of expression and activity of protein kinase CbetaII (PKCbetaII), and that this might influence disease progression by modulating signaling in response to B-cell receptor engagement. The aim of the present work was to investigate the factors involved in stimulating PKCbetaII expression in CLL cells. Here we show that the activation of PKCbetaII in CLL cells stimulated with vascular endothelial growth factor (VEGF) can drive expression of the gene for PKCbeta, PRKCB1. We found that this effect of VEGF on PRKCB1 transcription is paralleled by high expression of PKCbetaII protein and therefore probably contributes to the malignant phenotype of CLL cells. Taken together, the data presented in this study demonstrate that VEGF, in addition to its role in providing prosurvival signals, also plays a role in overexpression of PKCbetaII, an enzyme with a specific pathophysiologic role in CLL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164467     DOI: 10.1182/blood-2009-06-229872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 2.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

3.  Signal Transduction in Immune Cells and Protein Kinases.

Authors:  Monica Neagu; Carolina Constantin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Hun Ju Lee; Wei Qiao; William Wierda; Ohad Benjamini; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2014-07-15       Impact factor: 6.860

5.  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.

Authors:  Tait Shanafelt; Clive Zent; John Byrd; Charles Erlichman; Betsy Laplant; Asish Ghosh; Timothy Call; Miguel Villalona-Calero; Diane Jelinek; Deborah Bowen; Kristina Laumann; Wenting Wu; Curtis Hanson; Neil Kay
Journal:  Leuk Lymphoma       Date:  2010-11-05

6.  A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma.

Authors:  Lisa M Rimsza; Joseph M Unger; Margaret E Tome; Michael L Leblanc
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

7.  A case of comorbid myxoma and chronic lymphocytic leukemia: not just a coincidence?

Authors:  Heather Laird-Fick; Ashish Tiwari; Santhosshi Narayanan; Ying Qin; Deepthi Vodnala; Manisha Bhutani
Journal:  Case Rep Oncol Med       Date:  2014-04-29

8.  Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells.

Authors:  Ola Al-Sanabra; Andrew D Duckworth; Mark A Glenn; Benjamin R B Brown; Piera Angelillo; Kelvin Lee; John Herbert; Francesco Falciani; Nagesh Kalakonda; Joseph R Slupsky
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

Review 9.  Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?

Authors:  Joseph R Slupsky
Journal:  Scientifica (Cairo)       Date:  2014-07-02

Review 10.  Protein kinase C in cellular transformation: a valid target for therapy?

Authors:  Anuradha Tarafdar; Alison M Michie
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.